Company / Cash & Equivalents
TG Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$79.1M
FY2025
5-year range
$79.1M / $298.9M
FY2021-FY2025
Trend
-56.0%
vs FY2024
Sector context
#160 of 207
Health Care
What the data says
TG Therapeutics, Inc.'s cash & equivalents of $79M is lower than 77% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $25M in FY2016 to $553M in FY2020.
Based on SEC 10-K filings.
$79M in FY2025 with a 5-year CAGR of -32.2%.
Declined from $93M to $79M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -8.2%
- 5-Year CAGR
- -32.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 207This company $79.1M Sector average $669.5M
▼
-88.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -32.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 56.0% year-over-year.
- Ranks #160 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $79.1M | -56.0% |
| FY2024 | $179.9M | +93.6% |
| FY2023 | $92.9M | -9.2% |
| FY2022 | $102.3M | -65.8% |
| FY2021 | $298.9M | -46.0% |
| FY2020 | $553.4M | +1219.0% |
| FY2019 | $42.0M | +0.0% |
| FY2018 | $42.0M | -26.0% |
| FY2017 | $56.7M | +126.6% |
| FY2016 | $25.0M | -54.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026